New cancer drug karonudib tested in humans for first time
NCT ID NCT03036228
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This early-phase trial tested a new drug, Karonudib, in 63 people with advanced solid tumors that had not responded to other treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked for early signs that the drug might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karolinska University Hospital
Stockholm, Sweden
-
Sahlgrenska University Hospital
Gothenburg, Sweden
-
Uppsala University Hospital
Uppsala, Sweden
Conditions
Explore the condition pages connected to this study.